Table 2. Combination of MEK162 plus neratinib inhibits tumor growth in KRAS-mutant inflammatory cell line xenograft.

Tumor line	Tumor type	Subtype status	Mutation status	Dose/Schedule	% TGI* vs control	p-value
NCI-H747	colorectal	inflammatory	KRAS mut	Neratinib: 10mg/kg, QD	28%	p≥0.148 vs MEK162
				MEK-162: 3mg/kg, QD	37%	p≥0.148 vs Neratinib
				MEK-162 + Neratinib, QD	58%	p≥1.476E-06 vs Vehicle
				MEK-162 + Neratinib, QD		p≥0.0001 vs Neratinib alone
				MEK-162 + Neratinib, QD		p≥0.002 v MEK162 alone
SW-480	colorectal	stem-like	KRAS mut	Neratinib: 10mg/kg, QD	21%	p≥0.145 vs Vehicle
				MEK-162: 3mg/kg, QD	44%	p≥0.015 vs Neratinib
				MEK-162 + Neratinib, QD	47%	p = 0.5703 vs MEK162

*TGI (tumor growth inhibition)